List of studies reporting the outcomes of ovarian puncture after hormonal stimulation in Turner Syndrome patients.
| Study . | Patient no. . | Peripheral blood karyotype . | Age at ovarian stimulation . | Baseline FSH (IU/l) . | AMH (ng/ml) . | Number of retrieved oocytes . | Number of cryopreserved oocytes . | Use of oocytes (fresh/cryopreserved) . | IVF outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Ditkoff et al. (1996) | 1 | 46,XX/45,X0 | 33 | 6.8 | – | 21 | – | Fresh | Five fresh transferred embryos → 1 live birth, 8 cryopreserved embryos |
| Kavoussi et al. (2008) | 2* | NA | 28 | 4.3 | NA | 15 | 13 | No | – |
| Lau et al. (2009) | 3* | 45,X0 (98%)/47,XXX (2%) | 16 | 6.3 | NA | NA | 2 (MII) | No | – |
| Balen et al. (2010) | 4* | 45,X0 (93.3%)/46,XX (6.7%) | 28 | 3.3 (but 3 y before COS) | 6.1 | 9 MII, 2 MI, 1 GV | 0 (genetic analyses of these oocytes) | – | – |
10 | 7 | No | – | ||||||
| 20 | – | Fresh | 11 Day-2 cryopreserved embryos | ||||||
| El‐Shawarby et al. (2010) | 5* | 45,X0 (86%)/47,XXX (11%)/46,XX (3%) | 22 | 4.6 | 1.2 | 8 | 8 | No | – |
| Oktay et al. (2010) | 6* | 46,XX (55%)/45,X0 (45%) | 14 | 5.3 | 0.9 | 8 MII, 3 GV | 8 MII, 3 GV | No | – |
| 15 | NA | 1.7 | 4 MII, 3 immature oocytes | 4 MII, 3 immature oocytes | No | – | |||
| Oktay et al. (2014) | 7* | 45,X0 (90%)/47,XXX (10%) | 13 | 5.7 | 1.59 | 19 | 9 MII (+ 1 GV→MII after IVM) | No | – |
| 8* | 46,XX (80%)/45,X0 (20%) | 13 | 5.6 | 0.76 | 16 | 7 MII + (5 GV→MII after (IVM) | No | – | |
| Talaulikar et al. (2019) | 9* | 45,X0 (100%) | 22 | 6.9 | 0.5 | 6 MII, 3MI | 6 MII, 3MI | No | – |
| 10* | 45,X0 (83%)/46,XX (17%) | 18 | 3.2 | 0.4 | 8 MII, 1 MI, 4 oocytes | 8 MII, 1 MI | No | – | |
| 11* | 45,X0 (61%)/46,XX (39%) | 18 | 7.4 | 1 | 6 MII, 3MI | 6 MII, 3MI | No | – | |
| 12* | 45,X0/46,XX/47,XXX | 25 | 2.9 | 1.3 | 10 MII | 10 MII | No | – | |
| 13* | 45,X0 (63%)/46,XX (37%) | 21 | 6.2 | 0.5 | 4 MII | 4 MII | No | – | |
| 14* | 45,X0 (50%)/46,XX (50%) | 22 | 8.4 | 3 | 6 MII | 6 MII | No | – | |
| 15* | 45,X0 (88%)/46,XX (12%) | 26 | 7.5 | 1.7 | 10 MII, 2 MI | 10 MII, 2 MI | No | – | |
| Vergier et al. (2019) | 16* | 46,XX,del (Xp11.4) | 28 | 10 | 0.9 | 2 MII, 1 oocyte | 2 MII | No | – |
28 | 2 MII, 1 oocyte | 2 MII | |||||||
| 30 | 5 MII, 2 oocytes | 5 MII | |||||||
| 17* | 45,X0 (100%) | 25 | 6.5 | 8.8 | 17 MII, 3 oocytes | 17 MII | No | – | |
| 18* | 46,XX (83%)/45,X0 (9%)/46XderX (8%) | 18 | 5.9 | 2.5 | 20 MII, 5 oocytes | 20 MII | No | – | |
| Azem et al. (2020) | 19* | 45,X0 (71.2%)/47,XXX (28.8%) | 7 | 5.2 | 1.13 | 0 | – | – | – |
| 6 MII | 6 MII | No | – | ||||||
| Ito et al. (2020) | 20* | 45,X0 (13.3%)/46,XX (86.7%) | 23 | 10.6 | 3.43 | 9 MII | 9 MII | No | – |
| 8 MII, 1MI | 8 MII | ||||||||
| Grin et al. (2022) | 21 | 45,X0 (54.3%)/47,XXX (47.7%) | 30 (at first visit) | NA | NA |
| – | Fresh | One poor quality embryo, no embryo transfer |
| 22 | 45,X0 (94%)/47,XXX (6%) | 27 (at first visit) | NA | NA |
| – | Fresh | Two fair quality embryos, 1 single embryo transfer, 1 live birth | |
| 23 | 47,XXX (74%)/45,X0 (26%) | 27 (at first visit) | NA | NA |
| – | – | – | |
| 24 | 45,X0 (50%)/47,XXX (40%)/46,XX (10%) | 43 (at first visit) | NA | NA |
| – | Fresh | One fair and 2 poor quality embryos, 1 single embryo transfer, 0 clinical pregnancy | |
| Strypstein et al. (2022) | 25* | 46,XX (86%)/45,X0 (14%) | 24 | 3.4 | 6.4 | 8 MII | 8 MII | Cryopreserved | 11 good quality embryos, 3 good quality blastocyts, 2 euploid blastocysts after PGT-A, 2 single blastocyst transfers, 1 live birth |
| 21 MII | 21 MII | Cryopreserved | |||||||
| Martel et al. (2022) | 26* | Mosaic TS | 13 | 5.2 | 2.99 | 14 | 12 MII, 2 MI | No | – |
| 27* | 45,X0 (100%) | 14 | 0.4 | <0.16 | 4 | 2 MII, 1 MI, 1 GV | No | – | |
| 28* | Mosaic TS | 14 | 4.5 | 2.08 | 21 | 16 MII, 3 MI, 2 GV | No | – | |
| 29* | 45,X0 (100%) | 15 | 0.2 | ? | 15 | 15 MII | No | – | |
| 30* | Mosaic TS | 16 | 0.5 | 1.63 | 9 | 5 MII, 2 MI, 2 GV | No | – | |
| 16 | ? | ? | 10 | 3 MII, 4 MI, 2 GV | No | – | |||
| 31* | Mosaic TS | 17 | 1.1 | ? | 1 | 1 MI | No | – | |
| ? | ? | 1 | 1 MI | No | – | ||||
| ? | ? | 0 | 0 | No | – | ||||
| ? | ? | 1 | 1 MI | No | – | ||||
| 32* | Mosaic TS | 21 | 6.5 | 2.6 | 22 | 12 MII, 4 MI, 5 GV | No | – | |
| 33* | 45,X0 (100%) | 21 | 9.3 | <0.03 | 1 | 0 | No | – | |
| 21 | ? | ? | 1 | 0 | No | – | |||
| 34* | Mosaic TS | 21 | 5.4 | 5.34 | 19 | 14 MII, 5 GV | No | – |
| Study . | Patient no. . | Peripheral blood karyotype . | Age at ovarian stimulation . | Baseline FSH (IU/l) . | AMH (ng/ml) . | Number of retrieved oocytes . | Number of cryopreserved oocytes . | Use of oocytes (fresh/cryopreserved) . | IVF outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Ditkoff et al. (1996) | 1 | 46,XX/45,X0 | 33 | 6.8 | – | 21 | – | Fresh | Five fresh transferred embryos → 1 live birth, 8 cryopreserved embryos |
| Kavoussi et al. (2008) | 2* | NA | 28 | 4.3 | NA | 15 | 13 | No | – |
| Lau et al. (2009) | 3* | 45,X0 (98%)/47,XXX (2%) | 16 | 6.3 | NA | NA | 2 (MII) | No | – |
| Balen et al. (2010) | 4* | 45,X0 (93.3%)/46,XX (6.7%) | 28 | 3.3 (but 3 y before COS) | 6.1 | 9 MII, 2 MI, 1 GV | 0 (genetic analyses of these oocytes) | – | – |
10 | 7 | No | – | ||||||
| 20 | – | Fresh | 11 Day-2 cryopreserved embryos | ||||||
| El‐Shawarby et al. (2010) | 5* | 45,X0 (86%)/47,XXX (11%)/46,XX (3%) | 22 | 4.6 | 1.2 | 8 | 8 | No | – |
| Oktay et al. (2010) | 6* | 46,XX (55%)/45,X0 (45%) | 14 | 5.3 | 0.9 | 8 MII, 3 GV | 8 MII, 3 GV | No | – |
| 15 | NA | 1.7 | 4 MII, 3 immature oocytes | 4 MII, 3 immature oocytes | No | – | |||
| Oktay et al. (2014) | 7* | 45,X0 (90%)/47,XXX (10%) | 13 | 5.7 | 1.59 | 19 | 9 MII (+ 1 GV→MII after IVM) | No | – |
| 8* | 46,XX (80%)/45,X0 (20%) | 13 | 5.6 | 0.76 | 16 | 7 MII + (5 GV→MII after (IVM) | No | – | |
| Talaulikar et al. (2019) | 9* | 45,X0 (100%) | 22 | 6.9 | 0.5 | 6 MII, 3MI | 6 MII, 3MI | No | – |
| 10* | 45,X0 (83%)/46,XX (17%) | 18 | 3.2 | 0.4 | 8 MII, 1 MI, 4 oocytes | 8 MII, 1 MI | No | – | |
| 11* | 45,X0 (61%)/46,XX (39%) | 18 | 7.4 | 1 | 6 MII, 3MI | 6 MII, 3MI | No | – | |
| 12* | 45,X0/46,XX/47,XXX | 25 | 2.9 | 1.3 | 10 MII | 10 MII | No | – | |
| 13* | 45,X0 (63%)/46,XX (37%) | 21 | 6.2 | 0.5 | 4 MII | 4 MII | No | – | |
| 14* | 45,X0 (50%)/46,XX (50%) | 22 | 8.4 | 3 | 6 MII | 6 MII | No | – | |
| 15* | 45,X0 (88%)/46,XX (12%) | 26 | 7.5 | 1.7 | 10 MII, 2 MI | 10 MII, 2 MI | No | – | |
| Vergier et al. (2019) | 16* | 46,XX,del (Xp11.4) | 28 | 10 | 0.9 | 2 MII, 1 oocyte | 2 MII | No | – |
28 | 2 MII, 1 oocyte | 2 MII | |||||||
| 30 | 5 MII, 2 oocytes | 5 MII | |||||||
| 17* | 45,X0 (100%) | 25 | 6.5 | 8.8 | 17 MII, 3 oocytes | 17 MII | No | – | |
| 18* | 46,XX (83%)/45,X0 (9%)/46XderX (8%) | 18 | 5.9 | 2.5 | 20 MII, 5 oocytes | 20 MII | No | – | |
| Azem et al. (2020) | 19* | 45,X0 (71.2%)/47,XXX (28.8%) | 7 | 5.2 | 1.13 | 0 | – | – | – |
| 6 MII | 6 MII | No | – | ||||||
| Ito et al. (2020) | 20* | 45,X0 (13.3%)/46,XX (86.7%) | 23 | 10.6 | 3.43 | 9 MII | 9 MII | No | – |
| 8 MII, 1MI | 8 MII | ||||||||
| Grin et al. (2022) | 21 | 45,X0 (54.3%)/47,XXX (47.7%) | 30 (at first visit) | NA | NA |
| – | Fresh | One poor quality embryo, no embryo transfer |
| 22 | 45,X0 (94%)/47,XXX (6%) | 27 (at first visit) | NA | NA |
| – | Fresh | Two fair quality embryos, 1 single embryo transfer, 1 live birth | |
| 23 | 47,XXX (74%)/45,X0 (26%) | 27 (at first visit) | NA | NA |
| – | – | – | |
| 24 | 45,X0 (50%)/47,XXX (40%)/46,XX (10%) | 43 (at first visit) | NA | NA |
| – | Fresh | One fair and 2 poor quality embryos, 1 single embryo transfer, 0 clinical pregnancy | |
| Strypstein et al. (2022) | 25* | 46,XX (86%)/45,X0 (14%) | 24 | 3.4 | 6.4 | 8 MII | 8 MII | Cryopreserved | 11 good quality embryos, 3 good quality blastocyts, 2 euploid blastocysts after PGT-A, 2 single blastocyst transfers, 1 live birth |
| 21 MII | 21 MII | Cryopreserved | |||||||
| Martel et al. (2022) | 26* | Mosaic TS | 13 | 5.2 | 2.99 | 14 | 12 MII, 2 MI | No | – |
| 27* | 45,X0 (100%) | 14 | 0.4 | <0.16 | 4 | 2 MII, 1 MI, 1 GV | No | – | |
| 28* | Mosaic TS | 14 | 4.5 | 2.08 | 21 | 16 MII, 3 MI, 2 GV | No | – | |
| 29* | 45,X0 (100%) | 15 | 0.2 | ? | 15 | 15 MII | No | – | |
| 30* | Mosaic TS | 16 | 0.5 | 1.63 | 9 | 5 MII, 2 MI, 2 GV | No | – | |
| 16 | ? | ? | 10 | 3 MII, 4 MI, 2 GV | No | – | |||
| 31* | Mosaic TS | 17 | 1.1 | ? | 1 | 1 MI | No | – | |
| ? | ? | 1 | 1 MI | No | – | ||||
| ? | ? | 0 | 0 | No | – | ||||
| ? | ? | 1 | 1 MI | No | – | ||||
| 32* | Mosaic TS | 21 | 6.5 | 2.6 | 22 | 12 MII, 4 MI, 5 GV | No | – | |
| 33* | 45,X0 (100%) | 21 | 9.3 | <0.03 | 1 | 0 | No | – | |
| 21 | ? | ? | 1 | 0 | No | – | |||
| 34* | Mosaic TS | 21 | 5.4 | 5.34 | 19 | 14 MII, 5 GV | No | – |
Patients for whom the number of mature oocytes (Metaphase II) was specified are in bold. GV, germinal vesicle.
Patients who have benefited from oocyte cryopreservation.
List of studies reporting the outcomes of ovarian puncture after hormonal stimulation in Turner Syndrome patients.
| Study . | Patient no. . | Peripheral blood karyotype . | Age at ovarian stimulation . | Baseline FSH (IU/l) . | AMH (ng/ml) . | Number of retrieved oocytes . | Number of cryopreserved oocytes . | Use of oocytes (fresh/cryopreserved) . | IVF outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Ditkoff et al. (1996) | 1 | 46,XX/45,X0 | 33 | 6.8 | – | 21 | – | Fresh | Five fresh transferred embryos → 1 live birth, 8 cryopreserved embryos |
| Kavoussi et al. (2008) | 2* | NA | 28 | 4.3 | NA | 15 | 13 | No | – |
| Lau et al. (2009) | 3* | 45,X0 (98%)/47,XXX (2%) | 16 | 6.3 | NA | NA | 2 (MII) | No | – |
| Balen et al. (2010) | 4* | 45,X0 (93.3%)/46,XX (6.7%) | 28 | 3.3 (but 3 y before COS) | 6.1 | 9 MII, 2 MI, 1 GV | 0 (genetic analyses of these oocytes) | – | – |
10 | 7 | No | – | ||||||
| 20 | – | Fresh | 11 Day-2 cryopreserved embryos | ||||||
| El‐Shawarby et al. (2010) | 5* | 45,X0 (86%)/47,XXX (11%)/46,XX (3%) | 22 | 4.6 | 1.2 | 8 | 8 | No | – |
| Oktay et al. (2010) | 6* | 46,XX (55%)/45,X0 (45%) | 14 | 5.3 | 0.9 | 8 MII, 3 GV | 8 MII, 3 GV | No | – |
| 15 | NA | 1.7 | 4 MII, 3 immature oocytes | 4 MII, 3 immature oocytes | No | – | |||
| Oktay et al. (2014) | 7* | 45,X0 (90%)/47,XXX (10%) | 13 | 5.7 | 1.59 | 19 | 9 MII (+ 1 GV→MII after IVM) | No | – |
| 8* | 46,XX (80%)/45,X0 (20%) | 13 | 5.6 | 0.76 | 16 | 7 MII + (5 GV→MII after (IVM) | No | – | |
| Talaulikar et al. (2019) | 9* | 45,X0 (100%) | 22 | 6.9 | 0.5 | 6 MII, 3MI | 6 MII, 3MI | No | – |
| 10* | 45,X0 (83%)/46,XX (17%) | 18 | 3.2 | 0.4 | 8 MII, 1 MI, 4 oocytes | 8 MII, 1 MI | No | – | |
| 11* | 45,X0 (61%)/46,XX (39%) | 18 | 7.4 | 1 | 6 MII, 3MI | 6 MII, 3MI | No | – | |
| 12* | 45,X0/46,XX/47,XXX | 25 | 2.9 | 1.3 | 10 MII | 10 MII | No | – | |
| 13* | 45,X0 (63%)/46,XX (37%) | 21 | 6.2 | 0.5 | 4 MII | 4 MII | No | – | |
| 14* | 45,X0 (50%)/46,XX (50%) | 22 | 8.4 | 3 | 6 MII | 6 MII | No | – | |
| 15* | 45,X0 (88%)/46,XX (12%) | 26 | 7.5 | 1.7 | 10 MII, 2 MI | 10 MII, 2 MI | No | – | |
| Vergier et al. (2019) | 16* | 46,XX,del (Xp11.4) | 28 | 10 | 0.9 | 2 MII, 1 oocyte | 2 MII | No | – |
28 | 2 MII, 1 oocyte | 2 MII | |||||||
| 30 | 5 MII, 2 oocytes | 5 MII | |||||||
| 17* | 45,X0 (100%) | 25 | 6.5 | 8.8 | 17 MII, 3 oocytes | 17 MII | No | – | |
| 18* | 46,XX (83%)/45,X0 (9%)/46XderX (8%) | 18 | 5.9 | 2.5 | 20 MII, 5 oocytes | 20 MII | No | – | |
| Azem et al. (2020) | 19* | 45,X0 (71.2%)/47,XXX (28.8%) | 7 | 5.2 | 1.13 | 0 | – | – | – |
| 6 MII | 6 MII | No | – | ||||||
| Ito et al. (2020) | 20* | 45,X0 (13.3%)/46,XX (86.7%) | 23 | 10.6 | 3.43 | 9 MII | 9 MII | No | – |
| 8 MII, 1MI | 8 MII | ||||||||
| Grin et al. (2022) | 21 | 45,X0 (54.3%)/47,XXX (47.7%) | 30 (at first visit) | NA | NA |
| – | Fresh | One poor quality embryo, no embryo transfer |
| 22 | 45,X0 (94%)/47,XXX (6%) | 27 (at first visit) | NA | NA |
| – | Fresh | Two fair quality embryos, 1 single embryo transfer, 1 live birth | |
| 23 | 47,XXX (74%)/45,X0 (26%) | 27 (at first visit) | NA | NA |
| – | – | – | |
| 24 | 45,X0 (50%)/47,XXX (40%)/46,XX (10%) | 43 (at first visit) | NA | NA |
| – | Fresh | One fair and 2 poor quality embryos, 1 single embryo transfer, 0 clinical pregnancy | |
| Strypstein et al. (2022) | 25* | 46,XX (86%)/45,X0 (14%) | 24 | 3.4 | 6.4 | 8 MII | 8 MII | Cryopreserved | 11 good quality embryos, 3 good quality blastocyts, 2 euploid blastocysts after PGT-A, 2 single blastocyst transfers, 1 live birth |
| 21 MII | 21 MII | Cryopreserved | |||||||
| Martel et al. (2022) | 26* | Mosaic TS | 13 | 5.2 | 2.99 | 14 | 12 MII, 2 MI | No | – |
| 27* | 45,X0 (100%) | 14 | 0.4 | <0.16 | 4 | 2 MII, 1 MI, 1 GV | No | – | |
| 28* | Mosaic TS | 14 | 4.5 | 2.08 | 21 | 16 MII, 3 MI, 2 GV | No | – | |
| 29* | 45,X0 (100%) | 15 | 0.2 | ? | 15 | 15 MII | No | – | |
| 30* | Mosaic TS | 16 | 0.5 | 1.63 | 9 | 5 MII, 2 MI, 2 GV | No | – | |
| 16 | ? | ? | 10 | 3 MII, 4 MI, 2 GV | No | – | |||
| 31* | Mosaic TS | 17 | 1.1 | ? | 1 | 1 MI | No | – | |
| ? | ? | 1 | 1 MI | No | – | ||||
| ? | ? | 0 | 0 | No | – | ||||
| ? | ? | 1 | 1 MI | No | – | ||||
| 32* | Mosaic TS | 21 | 6.5 | 2.6 | 22 | 12 MII, 4 MI, 5 GV | No | – | |
| 33* | 45,X0 (100%) | 21 | 9.3 | <0.03 | 1 | 0 | No | – | |
| 21 | ? | ? | 1 | 0 | No | – | |||
| 34* | Mosaic TS | 21 | 5.4 | 5.34 | 19 | 14 MII, 5 GV | No | – |
| Study . | Patient no. . | Peripheral blood karyotype . | Age at ovarian stimulation . | Baseline FSH (IU/l) . | AMH (ng/ml) . | Number of retrieved oocytes . | Number of cryopreserved oocytes . | Use of oocytes (fresh/cryopreserved) . | IVF outcome . |
|---|---|---|---|---|---|---|---|---|---|
| Ditkoff et al. (1996) | 1 | 46,XX/45,X0 | 33 | 6.8 | – | 21 | – | Fresh | Five fresh transferred embryos → 1 live birth, 8 cryopreserved embryos |
| Kavoussi et al. (2008) | 2* | NA | 28 | 4.3 | NA | 15 | 13 | No | – |
| Lau et al. (2009) | 3* | 45,X0 (98%)/47,XXX (2%) | 16 | 6.3 | NA | NA | 2 (MII) | No | – |
| Balen et al. (2010) | 4* | 45,X0 (93.3%)/46,XX (6.7%) | 28 | 3.3 (but 3 y before COS) | 6.1 | 9 MII, 2 MI, 1 GV | 0 (genetic analyses of these oocytes) | – | – |
10 | 7 | No | – | ||||||
| 20 | – | Fresh | 11 Day-2 cryopreserved embryos | ||||||
| El‐Shawarby et al. (2010) | 5* | 45,X0 (86%)/47,XXX (11%)/46,XX (3%) | 22 | 4.6 | 1.2 | 8 | 8 | No | – |
| Oktay et al. (2010) | 6* | 46,XX (55%)/45,X0 (45%) | 14 | 5.3 | 0.9 | 8 MII, 3 GV | 8 MII, 3 GV | No | – |
| 15 | NA | 1.7 | 4 MII, 3 immature oocytes | 4 MII, 3 immature oocytes | No | – | |||
| Oktay et al. (2014) | 7* | 45,X0 (90%)/47,XXX (10%) | 13 | 5.7 | 1.59 | 19 | 9 MII (+ 1 GV→MII after IVM) | No | – |
| 8* | 46,XX (80%)/45,X0 (20%) | 13 | 5.6 | 0.76 | 16 | 7 MII + (5 GV→MII after (IVM) | No | – | |
| Talaulikar et al. (2019) | 9* | 45,X0 (100%) | 22 | 6.9 | 0.5 | 6 MII, 3MI | 6 MII, 3MI | No | – |
| 10* | 45,X0 (83%)/46,XX (17%) | 18 | 3.2 | 0.4 | 8 MII, 1 MI, 4 oocytes | 8 MII, 1 MI | No | – | |
| 11* | 45,X0 (61%)/46,XX (39%) | 18 | 7.4 | 1 | 6 MII, 3MI | 6 MII, 3MI | No | – | |
| 12* | 45,X0/46,XX/47,XXX | 25 | 2.9 | 1.3 | 10 MII | 10 MII | No | – | |
| 13* | 45,X0 (63%)/46,XX (37%) | 21 | 6.2 | 0.5 | 4 MII | 4 MII | No | – | |
| 14* | 45,X0 (50%)/46,XX (50%) | 22 | 8.4 | 3 | 6 MII | 6 MII | No | – | |
| 15* | 45,X0 (88%)/46,XX (12%) | 26 | 7.5 | 1.7 | 10 MII, 2 MI | 10 MII, 2 MI | No | – | |
| Vergier et al. (2019) | 16* | 46,XX,del (Xp11.4) | 28 | 10 | 0.9 | 2 MII, 1 oocyte | 2 MII | No | – |
28 | 2 MII, 1 oocyte | 2 MII | |||||||
| 30 | 5 MII, 2 oocytes | 5 MII | |||||||
| 17* | 45,X0 (100%) | 25 | 6.5 | 8.8 | 17 MII, 3 oocytes | 17 MII | No | – | |
| 18* | 46,XX (83%)/45,X0 (9%)/46XderX (8%) | 18 | 5.9 | 2.5 | 20 MII, 5 oocytes | 20 MII | No | – | |
| Azem et al. (2020) | 19* | 45,X0 (71.2%)/47,XXX (28.8%) | 7 | 5.2 | 1.13 | 0 | – | – | – |
| 6 MII | 6 MII | No | – | ||||||
| Ito et al. (2020) | 20* | 45,X0 (13.3%)/46,XX (86.7%) | 23 | 10.6 | 3.43 | 9 MII | 9 MII | No | – |
| 8 MII, 1MI | 8 MII | ||||||||
| Grin et al. (2022) | 21 | 45,X0 (54.3%)/47,XXX (47.7%) | 30 (at first visit) | NA | NA |
| – | Fresh | One poor quality embryo, no embryo transfer |
| 22 | 45,X0 (94%)/47,XXX (6%) | 27 (at first visit) | NA | NA |
| – | Fresh | Two fair quality embryos, 1 single embryo transfer, 1 live birth | |
| 23 | 47,XXX (74%)/45,X0 (26%) | 27 (at first visit) | NA | NA |
| – | – | – | |
| 24 | 45,X0 (50%)/47,XXX (40%)/46,XX (10%) | 43 (at first visit) | NA | NA |
| – | Fresh | One fair and 2 poor quality embryos, 1 single embryo transfer, 0 clinical pregnancy | |
| Strypstein et al. (2022) | 25* | 46,XX (86%)/45,X0 (14%) | 24 | 3.4 | 6.4 | 8 MII | 8 MII | Cryopreserved | 11 good quality embryos, 3 good quality blastocyts, 2 euploid blastocysts after PGT-A, 2 single blastocyst transfers, 1 live birth |
| 21 MII | 21 MII | Cryopreserved | |||||||
| Martel et al. (2022) | 26* | Mosaic TS | 13 | 5.2 | 2.99 | 14 | 12 MII, 2 MI | No | – |
| 27* | 45,X0 (100%) | 14 | 0.4 | <0.16 | 4 | 2 MII, 1 MI, 1 GV | No | – | |
| 28* | Mosaic TS | 14 | 4.5 | 2.08 | 21 | 16 MII, 3 MI, 2 GV | No | – | |
| 29* | 45,X0 (100%) | 15 | 0.2 | ? | 15 | 15 MII | No | – | |
| 30* | Mosaic TS | 16 | 0.5 | 1.63 | 9 | 5 MII, 2 MI, 2 GV | No | – | |
| 16 | ? | ? | 10 | 3 MII, 4 MI, 2 GV | No | – | |||
| 31* | Mosaic TS | 17 | 1.1 | ? | 1 | 1 MI | No | – | |
| ? | ? | 1 | 1 MI | No | – | ||||
| ? | ? | 0 | 0 | No | – | ||||
| ? | ? | 1 | 1 MI | No | – | ||||
| 32* | Mosaic TS | 21 | 6.5 | 2.6 | 22 | 12 MII, 4 MI, 5 GV | No | – | |
| 33* | 45,X0 (100%) | 21 | 9.3 | <0.03 | 1 | 0 | No | – | |
| 21 | ? | ? | 1 | 0 | No | – | |||
| 34* | Mosaic TS | 21 | 5.4 | 5.34 | 19 | 14 MII, 5 GV | No | – |
Patients for whom the number of mature oocytes (Metaphase II) was specified are in bold. GV, germinal vesicle.
Patients who have benefited from oocyte cryopreservation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
